Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Setmelanotide · Imcivree, RM-493

Peptide · Agonist of melanocortin 4 receptor (MC4R) · developed by Rhythm

Approved FDA, Nov 2020
RYTM Developer
1 Registered trials

What is Setmelanotide?

Setmelanotide is a melanocortin 4 (MC4) receptor agonist that acts on MC4 receptors in the brain, which regulate hunger, satiety and energy expenditure, to reduce food intake and promote weight loss. It has weaker activity at the MC3 and MC1 receptors. It is studied in Bardet-Biedl syndrome and Alstrom syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Imcivree, RM-493, BIM-22493
Drug type
Peptide
Targets
melanocortin 4 receptor (MC4R), melanocortin 3 receptor (MC3R) (secondary target), melanocortin 1 receptor (MC1R) (secondary target)
Mechanism
Agonist of melanocortin 4 receptor (MC4R)
Pathways
MC4 receptor pathway activity in the brain regulating hunger, satiety and energy, melanin accumulation in melanocytes
Therapy area
Neurology, Ophthalmology
Developer
Rhythm (RYTM)
FDA status
Approved as Imcivree (November 25, 2020), NDA213793 · FDA label
UNII
N7T15V1FUY

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 1, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07674290 Phase 4 Bardet Biedl Syndrome (BBS) Recruiting RYTM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alstrom SyndromeBardet Biedl SyndromeBardet Biedl Syndrome (BBS)

Other drugs acting on MC4R

More from Rhythm

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RYTM page.

Follow RYTM, the company behind Setmelanotide

See RYTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RYTM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.